Tiina Vesterinen1,2, Helena Leijon1, Harri Mustonen3, Satu Remes1, Aija Knuuttila4, Kaisa Salmenkivi1, Paula Vainio5, Johanna Arola1, Caj Haglund3,6. 1. HUSLAB, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 2. Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland. 3. Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 4. Department of Pulmonary Medicine, Heart and Lung Center and Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 5. Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland. 6. Research Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland.
Abstract
CONTEXT: Pulmonary carcinoids (PCs) belong to neuroendocrine tumors that often overexpress somatostatin receptors (SSTRs). This overexpression provides a molecular basis for tumor imaging and treatment with somatostatin analogs. OBJECTIVE: To evaluate SSTR1 to SSTR5 distribution in a large set of PC tumors and to investigate whether the expression is associated with clinicopathological and outcome data. DESIGN, SETTING, AND PATIENTS: This retrospective study was conducted at Helsinki University Hospital and University of Helsinki. It included 178 PC tumors coupled with patients' clinical data retrieved through Finnish biobanks. After histological reclassification, tissue specimens were processed into next-generation tissue microarray format and stained immunohistochemically with monoclonal SSTR1 to SSTR5 antibodies. MAIN OUTCOME MEASURE: SSTR1 to SSTR5 expression in PC tumors. RESULTS: Expression of SSTR1 to SSTR5 was detected in 52%, 75%, 56%, 16%, and 32% of the tumors, respectively. Membrane-bound staining was observed for all receptors. SSTR2 negativity and SSTR4 positivity was associated with lymph node involvement at the time of surgery (P = 0.014 and P = 0.017, respectively) and with distant metastasis (P = 0.027 and P = 0.015, respectively). SSTR3 and SSTR4 expression was associated with increased risk of shorter survival [P = 0.046, hazard ratio (HR) 4.703, 95% CI 1.027 to 21.533; and P = 0.013, HR 6.64, 95% CI 1.48 to 29.64, respectively], whereas expression of SSTR1 and SSTR2 was associated with improved outcome (P = 0.021, HR 0.167, 95% CI 0.037 to 0.765; and P = 0.022, HR 0.08, 95% CI 0.01 to 0.70, respectively). CONCLUSION: SSTR1 to SSTR5 expression is observed in PCs. As SSTR expression is associated with the tumor's metastatic potential and patient outcome, these receptors may offer the possibility for individualized prognosis estimation.
CONTEXT: Pulmonary carcinoids (PCs) belong to neuroendocrine tumors that often overexpress somatostatin receptors (SSTRs). This overexpression provides a molecular basis for tumor imaging and treatment with somatostatin analogs. OBJECTIVE: To evaluate SSTR1 to SSTR5 distribution in a large set of PC tumors and to investigate whether the expression is associated with clinicopathological and outcome data. DESIGN, SETTING, AND PATIENTS: This retrospective study was conducted at Helsinki University Hospital and University of Helsinki. It included 178 PC tumors coupled with patients' clinical data retrieved through Finnish biobanks. After histological reclassification, tissue specimens were processed into next-generation tissue microarray format and stained immunohistochemically with monoclonal SSTR1 to SSTR5 antibodies. MAIN OUTCOME MEASURE: SSTR1 to SSTR5 expression in PC tumors. RESULTS: Expression of SSTR1 to SSTR5 was detected in 52%, 75%, 56%, 16%, and 32% of the tumors, respectively. Membrane-bound staining was observed for all receptors. SSTR2 negativity and SSTR4 positivity was associated with lymph node involvement at the time of surgery (P = 0.014 and P = 0.017, respectively) and with distant metastasis (P = 0.027 and P = 0.015, respectively). SSTR3 and SSTR4 expression was associated with increased risk of shorter survival [P = 0.046, hazard ratio (HR) 4.703, 95% CI 1.027 to 21.533; and P = 0.013, HR 6.64, 95% CI 1.48 to 29.64, respectively], whereas expression of SSTR1 and SSTR2 was associated with improved outcome (P = 0.021, HR 0.167, 95% CI 0.037 to 0.765; and P = 0.022, HR 0.08, 95% CI 0.01 to 0.70, respectively). CONCLUSION:SSTR1 to SSTR5 expression is observed in PCs. As SSTR expression is associated with the tumor's metastatic potential and patient outcome, these receptors may offer the possibility for individualized prognosis estimation.
Authors: Marco Volante; Ozgur Mete; Giuseppe Pelosi; Anja C Roden; Ernst Jan M Speel; Silvia Uccella Journal: Endocr Pathol Date: 2021-02-27 Impact factor: 3.943
Authors: Susanna Majala; Tiina Vesterinen; Hanna Seppänen; Harri Mustonen; Jari Sundström; Camilla Schalin-Jäntti; Risto Gullichsen; Jukka Schildt; Jukka Kemppainen; Johanna Arola; Saila Kauhanen Journal: Cancers (Basel) Date: 2021-12-29 Impact factor: 6.639
Authors: Run Shi; Xuanwen Bao; Joachim Weischenfeldt; Christian Schaefer; Paul Rogowski; Nina-Sophie Schmidt-Hegemann; Kristian Unger; Kirsten Lauber; Xuanbin Wang; Alexander Buchner; Christian Stief; Thorsten Schlomm; Claus Belka; Minglun Li Journal: Cancers (Basel) Date: 2019-12-18 Impact factor: 6.639